Pharma News Update October 2026 Monthly

APPLY FOR PCD PHARMA FRANCHISE

October 2026 was a busy month for the Indian pharmaceutical industry. Regulatory inspections, new drug approvals, major business deals, and important policy changes kept companies and healthcare professionals on their toes. From USFDA inspections at major manufacturing sites to new cancer drug launches and changes in trade margins for oncology medicines, the month delivered news that will shape the industry for months to come.

This monthly roundup brings you all the important pharmaceutical industry news from 01 October 2026 to 31 October 2026. Whether you are a pharma professional, distributor, healthcare worker, or investor, this update will help you understand what changed and why it matters. We have arranged the news date-wise so you can follow the month's events easily.

Pharma News India Monthly readers will find this edition especially useful because it covers both regulatory actions and business developments. The month showed that quality compliance remains a top priority for Indian drugmakers. It also showed that Indian companies are expanding into advanced therapies like CAR-T and biosimilars.

Let us walk through the key developments of October 2026.

Monthly Pharma News: 01 October to 31 October 2026

06 October 2026: Indian Pharma Companies Show Strong Presence at Global Pharma Event

Background: Every year, Indian pharmaceutical companies participate in international trade shows to showcase their capabilities and connect with global buyers. These events are important for export growth and partnership building.

What happened: A large group of Indian pharma companies attended a major global pharmaceutical exhibition held in Milan, Italy, from 06 October to 08 October 2026. The Indian pavilion featured 67 companies, according to industry reports. The companies represented a mix of API manufacturers, formulation players, and contract service providers.

Why it matters: Global exhibitions are a key channel for Indian companies to attract international clients. With India being a major supplier of generic medicines and APIs, these events help strengthen the country's position in the global supply chain.

Impact: For Indian pharma companies, the event opened doors for new export orders and partnerships. For the healthcare industry, it means better access to affordable medicines in global markets. For the export market, participation in such events supports the growth of India's pharmaceutical shipments.

13 October 2026: Zydus Lifesciences Completes USFDA Inspection at Moraiya Plant

Background: The Moraiya facility in Ahmedabad is one of Zydus Lifesciences' key manufacturing sites for regulated markets. The plant produces formulations for the US and other markets.

What happened: Zydus Lifesciences informed stock exchanges on 13 October 2026 that a USFDA inspection had concluded at its Moraiya manufacturing plant. The inspection ran from 05 October to 13 October 2026 and resulted in five Form 483 observations. The company said it would work closely with the regulator to address the observations.

Why it matters: Form 483 observations are not automatic failures, but they signal areas where the FDA expects improvements. How a company responds to these observations often determines whether the facility faces further action. The Moraiya site is important for Zydus' US generics business.

Impact: For Zydus, a strong response to the observations will be crucial to maintain its US approval pipeline. For patients, there is no immediate impact on medicine supply. For investors, regulatory outcomes at key facilities are always closely watched because they affect future revenue from the US market.

14 October 2026: Expert Committee Recommends Approval of Boehringer Ingelheim's Lung Fibrosis Drug

Background: Progressive pulmonary fibrosis is a serious lung condition with limited treatment options in India. New therapies are needed to help patients manage the disease.

What happened: India's Subject Expert Committee for pulmonary drugs recommended import and marketing approval for Boehringer Ingelheim's nerandomilast tablets (9 mg and 18 mg) for progressive pulmonary fibrosis. The recommendation was made at a meeting on 14 October 2026. The approval is conditional on the company conducting phase IV trials in India, with the protocol submitted to CDSCO within three months.

Why it matters: This recommendation brings a new treatment option closer to Indian patients. The drug, marketed as Jascayd, is already approved in the US, EU, UK, and Japan. The committee noted an unmet medical need for PPF in India.

Impact: For patients with progressive pulmonary fibrosis, this offers hope for a new therapy. For Boehringer Ingelheim, it opens the Indian market for a specialty product. For the healthcare industry, it shows that CDSCO's expert committees are actively reviewing innovative medicines for rare and serious diseases.

15 October 2026: Mankind Pharma Enters CAR-T Therapy Space with Strategic Acquisition

Background: CAR-T cell therapy is a cutting-edge cancer treatment that modifies a patient's immune cells to fight cancer. This is a high-cost, high-complexity area that few Indian companies have entered.

What happened: Mankind Pharma announced on 15 October 2026 that it would acquire a majority stake in Armed Cell Therapeutics, marking its entry into next-generation CAR-T therapies. The acquisition is a strategic move for the Delhi-based company, which is already a major player in domestic formulations.

Why it matters: CAR-T therapy represents the future of personalized cancer treatment. By acquiring a stake in a cell therapy company, Mankind is positioning itself in a high-growth, high-value segment. This also shows that Indian companies are moving beyond traditional generics into advanced biologics and cell therapies.

Impact: For Mankind, this diversifies its portfolio and opens new revenue streams in specialty cancer care. For the healthcare industry, it signals growing domestic capability in cell and gene therapies. For patients, it may eventually lead to better access to CAR-T treatments within India rather than relying on imports.

17 October 2026: Government Finalises 30% Trade Margin Cap on 137 Cancer Drugs

Background: Cancer medicines are often expensive, and patient groups have long demanded price controls. The government has been working on a trade margin rationalization scheme for non-scheduled oncology drugs.

What happened: The government finalised a 30% trade margin cap on 137 non-scheduled cancer drugs on 17 October 2026. The new prices were set to come into effect from 09 November 2026, with state drug controllers responsible for monitoring implementation.

Why it matters: This is a major policy intervention aimed at reducing the cost of cancer treatment. However, the actual impact on patient bills is debated. Experts noted that patient assistance programmes are excluded from price calculations, which may limit the relief patients actually feel.

Impact: For patients, the cap may reduce the maximum retail price of some cancer drugs, but the real benefit depends on how hospitals and pharmacies pass it on. For pharmaceutical companies, margins on these products will be tighter. For investors, the policy adds a layer of pricing uncertainty in the oncology segment.

18 October 2026: Lupin Receives CDSCO Approval for Nivolumab Biosimilar

Background: Nivolumab is a checkpoint inhibitor used to treat several types of cancer, including melanoma and lung cancer. Biosimilars of this drug can make treatment more affordable.

What happened: Lupin received marketing approval from CDSCO for its nivolumab biosimilar, referencing Bristol Myers Squibb's Opdivo, on 18 October 2026. The approval is subject to Lupin conducting a Phase IV post-marketing study in India. The biosimilar was approved based on a local Phase III trial showing comparable efficacy and safety. Lupin will manufacture the product in partnership with Virchow Biotech.

Why it matters: This adds another affordable option in the immuno-oncology space. Zydus launched India's first nivolumab biosimilar in January 2026, followed by Dr. Reddy's in September 2026. Lupin's entry increases competition.

Impact: For patients, more biosimilar competition usually means lower prices over time. For Lupin, it strengthens its oncology portfolio. For the export market, successful biosimilar development in India supports the country's reputation as a quality supplier of complex biologics.

20 October 2026: Dr. Reddy's Receives DCGI Approval for Toripalimab for Esophageal Cancer

Background: Esophageal cancer is common in India, and new immunotherapy options are needed. Toripalimab is a PD-1 inhibitor developed in China and already approved in several countries.

What happened: Dr. Reddy's Laboratories received approval from the Drug Controller General of India for Zytorvi (toripalimab) for the treatment of esophageal cancer. The approval was reported on 20 October 2026. This marks another step in Dr. Reddy's expansion into oncology biosimilars and specialty products.

Why it matters: Toripalimab offers a new immunotherapy option for esophageal cancer patients in India. The approval also shows that Indian regulators are open to approving innovative drugs from global partners, even those originating from China, based on global data.

Impact: For patients, it provides another treatment choice for a difficult-to-treat cancer. For Dr. Reddy's, it adds to its growing oncology franchise. For the broader industry, it shows the increasing role of Indian companies as partners for global biotech innovations.

21 October 2026: Sanofi India Receives CDSCO Approval for Qfitlia for Haemophilia

Background: Haemophilia is a rare bleeding disorder that requires regular treatment. New treatment options can reduce the burden of frequent injections.

What happened: Sanofi received marketing authorisation from CDSCO for Qfitlia (fitusiran) for the treatment of haemophilia in India on 21 October 2026. Fitusiran is a novel therapy that uses RNA interference technology to reduce bleeding episodes.

Why it matters: Haemophilia treatment in India has traditionally relied on factor replacement therapy, which is expensive and requires frequent infusions. Fitusiran offers a different mechanism and potentially less frequent dosing, which could improve quality of life for patients.

Impact: For patients with haemophilia, this approval offers a new class of treatment. For Sanofi, it expands its rare disease portfolio in India. For the healthcare system, innovative haemophilia therapies can reduce the overall burden of managing bleeding episodes and hospitalizations.

21 October 2026: Sun Pharma Raises Rs 7,816 Crore Through Non-Convertible Debentures

Background: Sun Pharmaceutical Industries is India's largest pharma company and often raises capital for acquisitions, debt refinancing, or general corporate purposes.

What happened: Sun Pharma raised Rs 7,816 crore through the issuance of non-convertible debentures on 21 October 2026. The fundraise was one of the largest by an Indian pharma company in recent months.

Why it matters: A large capital raise by the market leader signals confidence in future growth opportunities. It could be used for acquisitions, capacity expansion, or strengthening the balance sheet. The timing is notable because Sun Pharma later reported a profit decline in Q2 FY27 due to litigation costs.

Impact: For investors, the NCD issuance provides a fixed-income investment option from a large, stable company. For the industry, it shows that capital markets remain open to well-rated pharma issuers. For Sun Pharma, the funds give it flexibility to pursue strategic priorities.

29 October 2026: India's Pharma Exports Grow 4.9% to $16.14 Billion in H1 FY27

Background: Pharmaceutical exports are a key driver of India's economy and a measure of the industry's global competitiveness. The first half of any fiscal year provides an important snapshot of export trends.

What happened: India's pharmaceutical exports rose 4.9% to $16.14 billion in the first half of FY27, according to data reported on 29 October 2026. Growth was driven by higher shipments to Europe, ASEAN, and Latin America, while exports to the US moderated.

Why it matters: The export growth shows that Indian pharma is diversifying beyond the US market. Europe and emerging markets are becoming important growth drivers. This is significant because the US market has faced pricing pressure and regulatory scrutiny in recent years.

Impact: For exporters, the data suggests opportunities in Europe and emerging markets. For the Indian pharma industry, diversified export growth reduces dependence on any single market. For investors, it indicates that companies with strong Europe and emerging market exposure may outperform those overly reliant on the US.

29 October 2026: Sanofi India Reports Strong Q3 2026 Results with 9% Diabetes Portfolio Growth

Background: Sanofi India is a major player in diabetes care in India. The company's quarterly results provide insight into the domestic chronic disease market.

What happened: Sanofi India delivered what it described as a strong Q3 2026 performance, led by 9% growth in its diabetes portfolio, according to a press release dated 29 October 2026. The company reported robust profit momentum.

Why it matters: Diabetes is a growing health concern in India, and the chronic therapy segment is a key growth driver for pharma companies. Sanofi's performance in this area reflects both the company's execution and the underlying demand for diabetes medicines.

Impact: For Sanofi India, the diabetes portfolio remains a core growth engine. For the healthcare industry, the results highlight the importance of chronic disease management in India's pharma market. For patients, continued investment in diabetes therapies means more treatment options and potentially better outcomes.

29 October 2026: Granules India's Gagillapur Facility Receives 11 USFDA Observations

Background: The Gagillapur facility in Hyderabad is a key finished dosage manufacturing site for Granules India. It had previously received a warning letter in February 2025, making this inspection particularly important.

What happened: Granules India announced that a USFDA inspection of its Gagillapur facility, conducted from 19 October to 30 October 2026, concluded with 11 Form 483 observations. The company stated that none of the observations related to data integrity or cross-contamination. The observations concerned investigations, change control, process and equipment qualification, visual inspection controls, and documentation. Granules said there was no impact on manufacturing or distribution, and it would submit a response within 15 business days.

Why it matters: This was the first USFDA inspection since the 2025 warning letter, so the outcome was closely watched. While 11 observations is a significant number, the company's statement that none involve data integrity is a positive signal. The nature of the observations suggests systemic quality system improvements are needed rather than fundamental failures.

Impact: For Granules, a strong corrective action plan is essential to avoid further regulatory escalation. For patients, there is no immediate supply disruption. For investors, the key will be whether the FDA classifies the inspection as Voluntary Action Indicated (VAI) or Official Action Indicated (OAI) after reviewing Granules' response.

30 October 2026: Government Mandates One-Year Minimum Residual Shelf Life for Imported Drugs

Background: Imported medicines often arrive in India with limited shelf life remaining, leading to wastage and supply issues. The previous rule required 60% residual shelf life.

What happened: The Health Ministry replaced the 60% residual shelf-life requirement with a fixed minimum of 12 months for most imported drugs, according to a report dated 30 October 2026. The change aims to ease imports and reduce wastage.

Why it matters: A clear, fixed rule is easier for importers to comply with than a percentage-based requirement. It also ensures that medicines arriving in India have enough shelf life to reach patients without expiring quickly.

Impact: For importers, the new rule provides clarity and may reduce rejections at customs. For patients, it means medicines are more likely to be usable for a longer period after arrival. For the healthcare system, less wastage translates to cost savings.

30 October 2026: CDSCO Asks States to Mandate Raw Material Testing by Drugmakers

Background: Recent incidents of contaminated cough syrups have raised concerns about the quality of raw materials used in medicine manufacturing. Regulatory oversight of raw material testing is being tightened.

What happened: CDSCO asked states and union territories to enforce raw material testing and vendor qualification by manufacturers, according to a report dated 30 October 2026. The directive follows concerns over contaminated cough syrups and drug safety.

Why it matters: Raw materials are the starting point of medicine production. If they are contaminated or substandard, the final product is at risk. This directive puts more responsibility on manufacturers to verify the quality of what they buy.

Impact: For drugmakers, compliance will require more rigorous testing protocols and better vendor management. For patients, the move strengthens the safety net around medicine quality. For the export market, stronger domestic quality controls can enhance India's reputation as a reliable supplier.

30 October 2026: Sun Pharma Reports Q2 FY27 Profit Decline of 36% on Litigation Costs

Background: Sun Pharma is India's largest pharma company and its quarterly results are a bellwether for the industry. The company has faced litigation costs related to various matters.

What happened: Sun Pharma reported a 36% decline in Q2 FY27 profit, attributed to litigation costs. The results were reported on 30 October 2026. Despite the profit decline, the company remains a dominant player in the domestic and US markets.

Why it matters: Litigation costs can be one-time or recurring, and investors need to understand the nature of these expenses. A profit decline at the market leader can affect sentiment across the sector, even if the underlying business remains strong.

Impact: For Sun Pharma, the focus will be on whether these costs are contained and whether the core business continues to grow. For investors, the results are a reminder that even large companies face earnings volatility from legal matters. For the industry, Sun's performance sets a tone for how other companies' results may be perceived.

31 October 2026: NPPA Cancer Drug Price Cuts Coverage Highlights Mixed Impact

Background: The 30% trade margin cap on 137 cancer drugs was finalized in mid-October. As the month ended, reports examined how the policy would actually affect prices and patients.

What happened: Reports on 29-31 October 2026 noted that the margin cap led to price reductions of up to 93% for some cancer medicines. However, major innovator brands saw no price reductions. Patient groups pointed out that patient assistance programmes were excluded from price calculations, diluting the relief.

Why it matters: The policy's effectiveness depends on how it is implemented and whether companies pass on the benefits to patients. The exclusion of patient assistance programmes from the calculation means that the actual out-of-pocket cost for many patients may not fall as much as the headline price cuts suggest.

Impact: For patients, the impact varies depending on which drug they need. For generic cancer drug makers, the cap may reduce margins. For innovator companies, the lack of price cuts on major brands means their revenue impact is limited. For the government, the policy's mixed reception suggests that further refinements may be needed.

Top 15–20 Key Pharma Headlines of October 2026

  1. Indian pharma companies participate in global pharma exhibition in Milan, showcasing 67 companies.
  2. Zydus Lifesciences receives 5 USFDA observations at Moraiya plant after inspection from 05-13 October.
  3. Boehringer Ingelheim's nerandomilast gets SEC recommendation for progressive pulmonary fibrosis.
  4. Mankind Pharma acquires majority stake in Armed Cell Therapeutics to enter CAR-T therapy.
  5. Government finalises 30% trade margin cap on 137 non-scheduled cancer drugs, effective 09 November.
  6. Lupin receives CDSCO approval for nivolumab biosimilar.
  7. Dr. Reddy's gets DCGI approval for Zytorvi (toripalimab) for esophageal cancer.
  8. Sanofi India receives CDSCO approval for Qfitlia (fitusiran) for haemophilia.
  9. Sun Pharma raises Rs 7,816 crore through NCDs.
  10. India's pharma exports grow 4.9% to $16.14 billion in H1 FY27.
  11. Sanofi India reports 9% growth in diabetes portfolio in Q3 2026.
  12. Granules India's Gagillapur facility receives 11 USFDA observations after inspection from 19-30 October.
  13. Government mandates one-year minimum residual shelf life for imported drugs.
  14. CDSCO directs states to enforce raw material testing by drugmakers.
  15. Sun Pharma reports 36% profit decline in Q2 FY27 on litigation costs.
  16. NPPA cancer drug margin cap leads to price cuts of up to 93% on some medicines.
  17. India's pharma and healthcare deal volumes rise 23% in Q3 2026, with 87 deals worth $4.3 billion.
  18. US exempts certain Indian specialty drugs and APIs from 100% tariff, while generics remain zero-tariff.
  19. Bajaj Healthcare reports 28.5% growth in API export revenue in Q2.
  20. Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business.

Industry Summary

The Indian pharmaceutical industry in October 2026 showed a mix of regulatory challenges and business progress. The month began with Indian companies making their presence felt at a global exhibition in Milan, reinforcing the country's role as a key player in the global pharma supply chain.

On the regulatory front, USFDA inspections at Zydus and Granules resulted in Form 483 observations. Neither inspection found data integrity issues, which is a positive sign, but the number of observations at Granules (11) indicates that quality system improvements are still needed. CDSCO was also active, directing states to enforce raw material testing and finalizing new rules on residual shelf life for imported drugs.

Drug approvals were a highlight of the month. Lupin's nivolumab biosimilar, Dr. Reddy's toripalimab, and Sanofi's fitusiran all received approvals, expanding treatment options for cancer and haemophilia patients. The SEC recommendation for Boehringer's nerandomilast added another potential new therapy for a serious lung condition.

The business side saw significant activity. Mankind Pharma's entry into CAR-T therapy through acquisition signals a shift toward advanced therapies. Sun Pharma's large NCD issuance shows that capital markets remain open to well-rated pharma issuers. Export data showing 4.9% growth in H1 FY27, driven by Europe and emerging markets, suggests that Indian pharma is successfully diversifying beyond the US.

The government's 30% trade margin cap on cancer drugs was a major policy development, though its actual impact on patient affordability remains debated. The exclusion of patient assistance programmes from price calculations has raised concerns among patient groups.

Looking ahead, the key themes for November will be the implementation of the cancer drug margin cap, the FDA's classification of the Zydus and Granules inspections, and whether export growth continues at the same pace. Companies with strong compliance records and diversified market exposure are likely to outperform.

FAQ Section

What are the top pharmaceutical trends for 2026?

The top trends include a shift toward advanced therapies like CAR-T and biosimilars, stricter regulatory compliance requirements, growth in chronic disease segments like diabetes, and diversification of export markets beyond the US. Indian companies are also increasingly partnering with global biotech firms for innovative products.

What are the latest pharma news updates this month?

October 2026 saw USFDA inspections at Zydus and Granules, new drug approvals for cancer and haemophilia, a major acquisition by Mankind Pharma in cell therapy, a 30% trade margin cap on cancer drugs, and export growth of 4.9% in H1 FY27.

What happened in the pharmaceutical industry during October 2026?

The industry experienced a mix of regulatory actions, product approvals, business deals, and policy changes. Key events included multiple USFDA inspections, several new drug approvals, Sun Pharma's Rs 7,816 crore fundraise, and the government's finalization of cancer drug margin caps.

Which pharmaceutical companies made major announcements this month?

Mankind Pharma announced a CAR-T therapy acquisition. Sun Pharma raised Rs 7,816 crore through NCDs. Granules and Zydus disclosed USFDA inspection outcomes. Lupin, Dr. Reddy's, and Sanofi received new drug approvals. Sanofi India and Mankind reported strong quarterly results.

Which medicines received important approvals in October 2026?

Key approvals included Lupin's nivolumab biosimilar, Dr. Reddy's Zytorvi (toripalimab) for esophageal cancer, and Sanofi's Qfitlia (fitusiran) for haemophilia. Boehringer Ingelheim's nerandomilast also received a positive SEC recommendation for progressive pulmonary fibrosis.

What are the biggest pharma industry updates in India?

The biggest updates include the 30% trade margin cap on 137 cancer drugs, CDSCO's directive on raw material testing, the new residual shelf life rule for imported drugs, and the strong export growth of 4.9% in H1 FY27.

Where can I find all monthly pharma industry news?

Visit GreenCrossIndia.com/blog for regular Monthly Pharma News Updates.

Why should healthcare professionals follow monthly pharma news?

Monthly pharma news helps healthcare professionals stay informed about new drug approvals, regulatory changes, quality alerts, and treatment options. This knowledge supports better clinical decisions and patient care.

What are the latest regulatory updates in India's pharmaceutical industry?

CDSCO directed states to enforce raw material testing by manufacturers. The Health Ministry mandated a one-year minimum residual shelf life for imported drugs. The NPPA implemented a 30% trade margin cap on 137 cancer drugs effective 09 November 2026.

What should pharma distributors and healthcare professionals know from this month's updates?

Distributors should be aware of the new cancer drug prices taking effect in November and the shelf life rule for imported drugs. Healthcare professionals should know about the new approvals for cancer and haemophilia treatments and the CDSCO directive on raw material quality.

Conclusion

October 2026 was a month of both progress and scrutiny for the Indian pharmaceutical industry. The industry demonstrated its global ambitions through participation in international events and entry into advanced therapy areas like CAR-T. At the same time, regulatory inspections at major manufacturing sites reminded companies that quality compliance is non-negotiable.

The month's drug approvals, particularly in oncology and rare diseases, expand treatment options for Indian patients. The government's policy moves on cancer drug margins, raw material testing, and imported drug shelf life show that regulators are actively working to balance affordability, quality, and access.

As we move into November, the industry will be watching how the cancer drug margin cap plays out in practice. The FDA's classification of the Zydus and Granules inspections will also be important for those companies' US market prospects. Export trends and quarterly results from more companies will provide further clues about the industry's direction.

For professionals and businesses in the pharma sector, staying informed about these developments is essential. The Pharma News India Monthly roundup will continue to bring you clear, verified updates every month.

Disclaimer: The information shared in this article is based on publicly available and verified pharmaceutical industry news published during 01 October 2026 to 31 October 2026. The content is prepared only for educational and informational purposes. While every effort has been made to ensure accuracy, readers are advised to verify important announcements with the respective pharmaceutical companies or regulatory authorities before making any business or professional decisions.


Reference List

  1. NSE India. Mankind Pharma Limited press release dated 15 October 2026.
  2. Pharmaceutical Ingredients Review. Granules India's Gagillapur facility receives 11 USFDA observations. 02 November 2026.
  3. MedPath Trial. India's SEC Recommends Approval of Boehringer Ingelheim's Nerandomilast for Progressive Pulmonary Fibrosis. 30 October 2026.
  4. Business Standard. Sanket Koul author page with October 2026 pharma news.
  5. NSE India. Sanofi India Limited press release dated 29 October 2026.
  6. CNBC TV18. Granules India's Gagillapur facility gets 11 observations in USFDA inspection. 29 October 2026.
  7. Lexology. Lupin's Biosimilar to BMS' Opdivo (Nivolumab) Approved in India. 18 October 2026.
  8. Chemical Week. Bajaj Healthcare records surge in formulations, API export revenues. 28 October 2026.
  9. NSE India. Zydus Lifesciences Limited press release dated 13 October 2026.
  10. MedPath Trial. Zydus Lifesciences Receives Five FDA Observations at Moraiya Manufacturing Facility. 25 October 2026.
  11. BioSpectrum India. Sanofi's Qfitlia (Fitusiran) receives marketing authorisation in India. 21 October 2026.
  12. TipRanks. Granules India's Gagillapur Plant Clears USFDA GMP Inspection With Eleven Observations. 29 October 2026. 



Chat With Us On Whatsapp For Pcd Pharma Franchise